July, 2022

article thumbnail

Amazon’s big gamble

World of DTC Marketing

Quick Read: Amazon will dramatically expand its healthcare reach with its planned $3.9 billion acquisition of One Medical, a primary care provider with 188 offices in 25 markets nationwide but are they making a strategic move or a mistake? Telehealth has a future, but one could argue that physicians need to see patients firsthand to diagnose and evaluate patients.

Doctors 283
article thumbnail

Announcing changes to the 2023 Journal Citation Reports

Clarivate

Starting from the 2023 JCR release, Journal Impact Factors will be expanded to all Web of Science Core Collection journals including arts and humanities. Today we’re proud to announce that in the 2023 release of the Journal Citation Reports , all Web of Science Core Collection journals will receive a Journal Impact Factor (JIF). This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citati

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

With new $670M healthcare fund, General Catalyst seeks more health system partners

MedCity News

General Catalyst recently launched a $670 million healthcare investment fund. The fund, called Health Assurance Fund II, seeks to carry on the mission of the venture capital firm’s first healthcare-focused fund, but with a new focus on health system partnerships.

article thumbnail

Connecting your Digital Health Strategy from Clinical to Commercial

PharmExec

Thursday, July 21st 2022 at 11am EST, 8am PST, 5pm CEST Join this webinar to hear industry thought leaders discuss how data and experiences serve clinical and commercial needs, explore which platforms and technologies can enable a robust digital health ecosystem, and share recommendations for building a digital health strategy fit for your business.

139
139
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Controlling contamination by material transfer

European Pharmaceutical Review

Ensuring potential microbial contaminants are not transferred into cleanroom environments is a key aspect of risk mitigation strategies. In a review, pharmaceutical microbiologist and contamination control expert Tim Sandle, reviewed several methods of material transfer, listing the decontamination methods based on efficacy and commenting on their weaknesses. .

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative.

More Trending

article thumbnail

Macmillan alliance will provide digital health apps to cancer patients

pharmaphorum

Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health. The alliance, billed as the first of its kind in the UK, means that cancer patients will be able to use Big Health apps like Sleepio and Daylight, which aim to treat insomnia and anxiety using cognitive behavioural therapy (CBT) techniques.

Patients 133
article thumbnail

Reimagining healthcare in a quantum era

MedCity News

With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be prepared to invest in quantum technologies to deliver better outcomes for their organizations and patients.

article thumbnail

Personalizing the Cancer Patient Journey

Pharma Marketing Network

In the first two weeks after a cancer diagnosis, there are likely dozens of doctor’s visits, tests, consultations, and decision points. The patient care team supplies an abundance of information, although sifting through brochures and online resources can be daunting for the patient and their caregiver. Adhering to regulatory guidelines is an important step pharma takes to ensure that promotional medical materials contain balanced information that is accurate and relevant. 1 The marketer’s goal

Patients 130
article thumbnail

Brain-Computer Interfaces at Home: Interview with Dr. Solzbacher of Blackrock Neurotech

Medgadget

Blackrock Neurotech , a medtech company based in Salt Lake City, has pioneered an array of brain-computer interface technologies. Medgadget last spoke with Blackrock Neurotech a year ago about their thought-to-text brain computer interface, but since the company signed an agreement with a research institution to develop portable brain computer interface (BCI) systems.

Medical 127
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Is biotech facing a long bear market?

Pharmaceutical Technology

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7. Elsewhere, San Diego, California-based Heron Therapeutics announced restructuring and layoffs for 34% of its workforce.

Marketing 129
article thumbnail

Pharma’s platinum handcuffs

World of DTC Marketing

To address the “retention” problem, pharma companies are paying employees exorbitant salaries. The problem with that system is that people do whatever they need to to “hold onto” their high-paying jobs and become employees who are content not to excel. This is NOT what pharma needs. Last week I briefly chatted with someone in the industry evaluating another job offer.

Pharma 257
article thumbnail

Twill taps YourCoach for DtX-health coaching integration

pharmaphorum

Health coaching ecosystem YourCoach Health and digital therapeutics company Twill (formerly Happify Health ) are teaming up to offer access to YourCoach’s cross-specialty health coaches via Twill’s Duet platform, the companies announced today. “Digital therapy has been around for a really long time,” YourCoach Cofounder and CEO Marina Borukhovich told pharmaphorum.

article thumbnail

Digital health investment is just cooling off after a scorching year

MedCity News

Digital health startups raised $10.3 billion across 329 deals during the first half of 2022. This putts the sector on track to rake in $21 billion this year, about $8 billion less than the total amount it raised in 2021. The market boom has ended, but the digital health investment space has not come crashing down by any means, according to a recent report.

Marketing 142
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Microbial risks presented by aging facilities

European Pharmaceutical Review

As established facilities age, various risk considerations emerge. While some may continue to function effectively without any additional considerations, many will require additional checks and assessment. In an article published in the Journal of Validation Technology (JVT), pharmaceutical microbiologist and contamination control expert Tim Sandle identified ten categories of risk presented by aging.

article thumbnail

It Takes a Village: How Pharma Can Help Address the Mental Health and Substance Abuse Crisis

PM360

The COVID-19 pandemic led to an increase in depression and anxiety, along with an increase in opioid use and overdose. At the same time, emergency needs for COVID-19 vaccination and treatment captured the health community’s attention, and the focus on substance abuse treatment faltered. As a result of the worsening mental health issues and decreased attention to substance use, the United States saw an increase in alcohol and opioid use, resulting in additional comorbidities and deaths.

Pharma 116
article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.

Marketing 122
article thumbnail

Self-Powered Implant Tracks Spinal Fusion Healing

Medgadget

Engineers at the University of Pittsburgh created a self-powered implant that can track spinal healing while also providing mechanical support. The device can be 3D printed so that it fits a given patient perfectly and the mechanical properties can also be easily tuned to customize for each situation. The spinal fusion cage contains a triboelectric nanogenerator that creates electricity when it is pressurized by the spine.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

pharmaphorum

The pharmaceutical industry is increasingly relying on artificial intelligence to power its drug discovery and development efforts, and its spend in this area has created a multibillion-dollar market for AI technologies. That’s the conclusion of a GlobalData report , which notes that AI is being used to enhance computer-aided drug design (CADD) in a bid to reduce the time and costs involved in getting a new drug to market.

Marketing 129
article thumbnail

Elevating patient care from the home

MedCity News

By adding adherence and connectivity capabilities to home-based solutions, clinicians can maintain open lines of communication with patients, helping patients better care for themselves from the comfort of their homes.

Patients 143
article thumbnail

Pfizer to reach carbon net-zero by 2040

European Pharmaceutical Review

After more than 20 years of environmental action, Pfizer has committed to further reduce its greenhouse gas (GHG) emissions and aims to achieve the voluntary Net-Zero Standard by 2040 – a full 10 years ahead of the standard’s proposed timeline. To achieve these goals, Pfizer aims to decrease its GHG emissions by 95 percent and its value chain emissions by 90 percent from 2019 levels by 2040.

article thumbnail

Lupus discovery lends clues to the fight against long COVID

PharmaVoice

So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki help lead the way.

Pharma 119
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

GSK acquires US-based Sierra Oncology for $1.9bn

Pharmaceutical Technology

GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. The conclusion of the deal comes after the shareholders of Sierra Oncology approved the takeover on 29 June this year.

article thumbnail

AI-Powered Robot Accelerates Medical Research

Medgadget

Researchers at the RIKEN Center for Biosystems Dynamics Research in Japan have developed an AI-powered robotic system that can perform laboratory experiments in regenerative medicine, learn from the results, and perform iterative rounds of experimentation to achieve a certain goal. In a proof-of-principle, the researchers set the robot the task of optimizing cell culture conditions to create a maximal number of retinal pigment epithelium (RPE) cells.

Medical 113
article thumbnail

AstraZeneca agrees $1.3bn deal to buy oncology player TeneoTwo

pharmaphorum

AstraZeneca has signed a deal to buy US biotech TeneoTwo in a deal worth up to $1.27 billion that will boost its position therapies for haematological cancers. The big pharma is paying $100 million upfront for the company, and offering up to $805 million in milestone payments if TeneoTwo’s drug candidates meet development objectives, plus up to $360 million if they hit sales targets.

Pharma 123
article thumbnail

CVS scheme diverted millions from underserved population, NY AG says

MedCity News

Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

article thumbnail

6 Important Messages When Marketing Healthcare to Gen Z

PM360

A new generation is coming of age, which is big news for healthcare marketers. Members of Generation Z, currently in their teens and early 20s, will soon be taking charge of their own healthcare for the first time in their lives. Within the next few years, Gen Zers will stop qualifying for health insurance coverage through their parents and will become more independent, financially and otherwise.

article thumbnail

Research integrity: five tips for authors, editors and reviewers

Clarivate

The Web of Science is taking steps to help the research community better understand research integrity. In this blog post, we discuss our free courses in the Web of Science Academy, new features including ‘retraction alerts’ and share some practical tips for researchers to help uphold research integrity in their everyday work and research community.

Ethics 105
article thumbnail

Russia’s focus on domestic pharma production could shield it from sanctions’ effects

Pharmaceutical Technology

Russia is an already insular country and its worldview has tended to be self-contained, but this has hardened in the face of recent sanctions and counter-sanctions imposed during the war with Ukraine. Compared with other emerging pharmaceutical markets (such as India and China, covered in previous Emerging Market Outsourcing Reports), Russian facilities lack many US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, meaning Russian manufacturing is more focused on

Pharma 122
article thumbnail

Face Mask Deactivates SARS-CoV-2 Spike Protein

Medgadget

Researchers at the University of Kentucky created a novel membrane that can enzymatically degrade the SARS-CoV-2 spike protein, rendering the virus inactive. The membrane is intended to act as an insert within face masks, providing extra protection for groups at high risk of SARS-CoV-2 exposure, such as health care staff. The researchers functionalized the membrane with subtilisin enzyme, which can degrade the spike protein in as little as 30 seconds.

article thumbnail

Clinical Supply Strategies for CROs

When a CRO is bidding on a project where clinical supplies will be one of the aspects to manage on behalf of the client via a partner, leveraging the expertise of a chosen clinical supply partner can be a valuable resource in demonstrating the CRO’s understanding of and ability to deliver upon critical drug-supply related aspects of the project, and ability to hit key milestones such as FPI for their client.